Insmed slides after May 7 Q1 results show revenue miss despite reiterated guidance
INSM•Insmed reported Q1 2026 results and a business update on May 7, 2026, including total revenue of about $306.0 million and BRINSUPRI revenue of $207.9 million. Shares moved lower as the report implied a revenue miss versus expectations while the company reiterated full-year 2026 product revenue guidance.
1) What happened today (May 7, 2026)
Insmed released first-quarter 2026 financial results and provided a business update today. The company reported total revenue of roughly $306.0 million and BRINSUPRI revenue of $207.9 million, and reiterated its 2026 revenue guidance ranges for key products.
2) Why the stock moved
The day’s move appears tied to the earnings release and investor read-through that quarterly revenue came in below expectations, despite a narrower loss and reiterated full-year guidance. With INSM having run up into expectations around the BRINSUPRI launch ramp and pipeline progress, the quarterly top-line print and tone around near-term trajectory likely drove the selloff.
3) What to watch next
Key follow-ups are any additional detail from the earnings call on BRINSUPRI demand trends, payer/formulary dynamics, and quarterly cadence implied by the reiterated full-year guidance. Investors will also watch for timing and specifics around ARIKAYCE label-expansion plans and upcoming Phase 3 program initiations mentioned in the business update.
